The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
Stocks are bouncing higher but could be trapped in a range longer term, until there's a resolution of the trade wars.Market Insiderread more
Powell will have the opportunity if not to walk back the "midcycle" assessment then to at least provide some further explanation about what it means.Economyread more
The report comes as Trump in recent days has lashed out over media reports about growing recession fears.Politicsread more
Apple has spent more than $6 billion on original TV shows and movies for its forthcoming Apple TV+ service, according to a Financial Times report on Monday.Technologyread more
The Business Roundtable, led by Jamie Dimon, gives a new definition of the "purpose of a corporation."Marketsread more
Tilman Fertitta told CNBC on Monday that he is doing things in a "very conservative way" amid fears of a recession.Marketsread more
Saudi Aramco sent a request for proposal to several banks, people familiar with the matter told CNBC on Monday.Marketsread more
Twitter and Facebook have suspended accounts believed to be tied to a state-backed disinformation campaign originating from inside China.Technologyread more
Leaked documents from Google give fresh ammo to conservative lawmakers who have already accused Google and other tech companies of political bias.Technologyread more
J.P. Morgan estimates the average annual tariff cost per household will be $1,000 with the new round of Trump's tariffs.Marketsread more
(Adds details, background, forecast, estimates)
July 30 (Reuters) - Gilead Sciences Inc beat analysts' estimates for quarterly revenue on Tuesday, driven by higher sales of its HIV treatments, and the drugmaker raised its 2019 sales forecast.
The company is expanding into newer therapeutic areas under new Chief Executive Officer Daniel O'Day as the hepatitis C market it once dominated contracts.
O'Day, a Roche veteran who took charge in March, has made strengthening Gilead's drug development pipeline, both internally as well as through acquisitions or partnerships, his first priority.
The company earlier this month announced a $5.1 billion investment in Belgo-Dutch biotech Galapagos NV, deepening a partnership and pushing deeper into fibrosis and arthritis treatments.
The California-based company said on Tuesday it now expects sales of $21.6 billion to $22.1 billion in 2019, compared with its prior forecast of $21.3 billion to $21.8 billion.
Total revenue rose to $5.69 billion in the second quarter, beating the average analyst estimate of $5.53 billion, according to IBES data from Refinitiv.
Sales of Gilead's HIV drugs, which accounted for about 71% of the company's total sales, rose to $4.04 billion from $3.67 billion. The sales jump was driven by demand for its new HIV treatment Biktarvy, the company said.
Biktarvy sales surged to $1.12 billion from $185 million, a year earlier.
Sales of hepatitis C drugs dropped again, falling to $842 million from $1.0 billion, as many patients have been cured of the liver-damaging virus and rival products, particularly from AbbVie, have captured market share from a shrinking patient pool.
Net income attributable to Gilead rose to $1.88 billion, or $1.47 per share, in the second quarter ended June 30, from $1.82 billion, or $1.39 per share, a year earlier.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)